¼¼°èÀÇ ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ºÐ¼® ½ÃÀå
Bioprocessing Analytics
»óǰÄÚµå : 1796105
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 371 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,186,000
PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÆÄÀÏ ³» ÅØ½ºÆ®ÀÇ º¹»ç ¹× ºÙ¿©³Ö±â´Â °¡´ÉÇÏÁö¸¸, Ç¥/±×·¡ÇÁ µîÀº º¹»çÇÒ ¼ö ¾ø½À´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,559,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ¹× 100% ÀÚȸ»çÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1Àδç 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ºÐ¼® ¼¼°è ½ÃÀåÀº 2030³â±îÁö 6¾ï 5,050¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 5¾ï 3,740¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ºÐ¼® ¼¼°è ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2024-2030³â¿¡ CAGR 3.2%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 6¾ï 5,050¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀΠħÅõ¾Ð°è´Â CAGR 2.6%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 4¾ï 1,450¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ºÐ¼®±â ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 4.5%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 1¾ï 4,640¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 5.9%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ºÐ¼® ½ÃÀåÀº 2024³â¿¡ 1¾ï 4,640¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGR 5.9%·Î 2030³â±îÁö 1¾ï 2,760¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 1.3%¿Í 2.5%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 1.8%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ºÐ¼® ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ºÐ¼®ÀÌ ¹ÙÀÌ¿ÀÀǾàǰ Á¦Á¶ÀÇ ÇÙ½ÉÀÌ µÇ°í ÀÖ´Â ÀÌÀ¯´Â ¹«¾ùÀϱî?

»ý¹°ÇÐÀû Á¦Á¦ÀÇ º¹À⼺°ú Á¦Á¶¿¡ µû¸¥ ³ôÀº À§Ç輺À¸·Î ÀÎÇØ ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ºÐ¼®Àº »ý¹°ÇÐÀû Á¦Á¦ Á¦Á¶ °øÁ¤¿¡¼­ ÇʼöÀûÀÎ ¿ä¼Ò·Î ÀÚ¸® Àâ¾Ò½À´Ï´Ù. ´ÜŬ·ÐÇ×ü, ¼¼Æ÷ Ä¡·áÁ¦, À¯ÀüÀÚ Ä¡·áÁ¦ µî »ý¹°ÇÐÀû Á¦Á¦°¡ ÁÖ¸ñ¹ÞÀ¸¸é¼­ À̵é Á¦Ç°ÀÇ Àϰü¼º, ¾ÈÀü¼º, À¯È¿¼ºÀ» Á¦Á¶ ¶óÀÌÇÁ»çÀÌŬ Àü¹Ý¿¡ °ÉÃÄ È®º¸ÇÏ´Â °ÍÀÌ ÇʼöÀûÀÔ´Ï´Ù. ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ºÐ¼®Àº Áß¿äÇÑ Ç°Áú ¼Ó¼º°ú °øÁ¤ ÆÄ¶ó¹ÌÅ͸¦ ½Ç½Ã°£ ¹× ¿ÀÇÁ¶óÀÎÀ¸·Î ¸ð´ÏÅ͸µÇÔÀ¸·Î½á Á¦Á¶¾÷ü°¡ ÆíÂ÷¸¦ °¨ÁöÇÏ°í ¼öÀ²À» ÃÖÀûÈ­ÇÏ¸ç ±ÔÁ¦ Áؼö¸¦ À¯ÁöÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù. »ý»ê ÈÄ ºÐ¼®¿¡ Å©°Ô ÀÇÁ¸ÇÏ´ø ±âÁ¸ÀÇ Ç°Áú °Ë»ç ¹æ¹ýÀº ¾÷½ºÆ®¸²¿¡¼­ ´Ù¿î½ºÆ®¸²±îÁö Àü °øÁ¤¿¡ °ÉÃÄ Áö¼ÓÀûÀÎ ¸ð´ÏÅ͸µ°ú Á¦¾î¸¦ °¡´ÉÇÏ°Ô ÇÏ´Â ÅëÇÕ ºÐ¼® µµ±¸·Î ´ëüµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¯È­´Â ±ÔÁ¦ ´ç±¹ÀÌ ÁÖÀåÇÏ´Â QbD(Quality by Design)¿Í PAT(Process Analytical Technology)ÀÇ ÇÁ·¹ÀÓ¿öÅ©¸¦ ÁöÇâÇÏ´Â ¾÷°èÀÇ ¿òÁ÷ÀÓ°ú ÀÏÄ¡ÇÕ´Ï´Ù. ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ºÐ¼®Àº »ý»ê ÆÄÀÌÇÁ¶óÀÎÀÇ °¢ ´Ü°è¿¡¼­ ½Ç¿ëÀûÀÎ ÀλçÀÌÆ®¸¦ Á¦°øÇÏ¿© ¹èÄ¡ ºÒ·® °¨¼Ò, ºñ¿ë ÃÖ¼ÒÈ­, ½ÃÀå Ãâ½Ã ½Ã°£ ´ÜÃàÀ» Áö¿øÇÕ´Ï´Ù. ÀÏȸ¿ë ±â¼ú ¹× ¿¬¼Ó »ý»êÀÇ »ç¿ëÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¿ªµ¿ÀûÀÎ Á¦Á¶ ȯ°æ¿¡ ´ëÀÀÇÒ ¼ö ÀÖ´Â °­·ÂÇÑ ºÐ¼®ÀÇ Çʿ伺ÀÌ ´õ¿í Ä¿Áö°í ÀÖ½À´Ï´Ù. »ý¹°ÇÐÀû Á¦Á¦¿¡ ´ëÇÑ ¼¼°è ¼ö¿ä°¡ Áõ°¡Çϰí Ä¡·á¹ýÀÌ È¯ÀÚ ¸ÂÃãÇüÀ¸·Î º¯È­ÇÔ¿¡ µû¶ó, ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ºÐ¼®Àº ¹ÙÀÌ¿À Á¦Á¶ÀÇ ¿î¿µÀû ¿ì¼ö¼º°ú ±ÔÁ¦Àû ¼º°øÀ» ´Þ¼ºÇϱâ À§ÇÑ Ãʼ® ¿ªÇÒÀ» °è¼ÓÇÒ °ÍÀÔ´Ï´Ù.

±â¼ú Çõ½ÅÀº ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ºÐ¼®ÀÇ ¹üÀ§¿Í Á¤È®¼ºÀ» ¾î¶»°Ô ÀçÁ¤ÀÇÇϰí Àִ°¡?

¼¾¼­ ±â¼ú, µ¥ÀÌÅÍ ºÐ¼®, ¸Ó½Å·¯´×, ÀÚµ¿È­ÀÇ ±Þ¼ÓÇÑ ¹ßÀüÀº ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ºÐ¼®À» ½Ç½Ã°£ Á¦Á¶ ȯ°æ¿¡ ±¸ÇöÇϰí Ȱ¿ëÇÏ´Â ¹æ¹ýÀ» ÀçÁ¤ÀÇÇϰí ÀÖ½À´Ï´Ù. ÃֽйÙÀÌ¿ÀÇÁ·Î¼¼½Ì ½Ã½ºÅÛ¿¡´Â pH, ¿ëÁ¸ »ê¼Ò, ¿Âµµ, ʵµ, ¼¼Æ÷ ¹Ðµµ, ´ë»ç»ê¹° ³óµµ µîÀÇ ÆÄ¶ó¹ÌÅ͸¦ Àü·Ê ¾ø´Â Á¤¹Ðµµ·Î ¿¬¼ÓÀûÀ¸·Î ¸ð´ÏÅ͸µÇÒ ¼ö Àִ ÷´Ü ÀζóÀÎ ¼¾¼­¿Í ¾Ü¶óÀÎ ¼¾¼­°¡ ÀåÂøµÇ¾î ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¼¾¼­´Â ¿¹ÃøÀû Á¶Á¤À» °¡´ÉÇÏ°Ô ÇÏ´Â Á¤±³ÇÑ Á¦¾î ½Ã½ºÅÛ¿¡ µ¥ÀÌÅ͸¦ Á¦°øÇÏ¿© ÃÖÀûÀÇ Á¶°ÇÀ» À¯ÁöÇϰí Àüü °øÁ¤ÀÇ ¾ÈÁ¤¼ºÀ» Çâ»ó½ÃŰ´Â µ¥ µµ¿òÀ» ÁÝ´Ï´Ù. µ¿½Ã¿¡ ±â°èÇнÀ ¾Ë°í¸®Áò°ú ÀΰøÁö´ÉÀÌ »ý»ê °úÁ¤¿¡¼­ »ý¼ºµÇ´Â ¹æ´ëÇÑ µ¥ÀÌÅͼ¼Æ®ÀÇ ºÐ¼®¿¡ äÅÃµÇ¾î ¼öÀÛ¾÷ ¸ð´ÏÅ͸µ¸¸À¸·Î´Â ºÒ°¡´ÉÇÑ ÀÌ»ó ¡Èĸ¦ Á¶±â¿¡ ¹ß°ßÇÏ°í ÆÐÅÏÀ» ÀνÄÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. Ŭ¶ó¿ìµå ±â¹Ý Ç÷§Æû°ú ÅëÇÕ ¼ÒÇÁÆ®¿þ¾î Á¦Ç°±ºÀº µ¥ÀÌÅÍÀÇ Áß¾Ó ÁýÁᫎ °ü¸®, ¿ø°Ý ¾×¼¼½º, »çÀÌÆ® °£ ºñ±³¸¦ ¿ëÀÌÇÏ°Ô ÇÏ¿© ¿©·¯ ½Ã¼³À» °ü¸®ÇÏ´Â ´Ù±¹Àû ±â¾÷¿¡°Ô ƯÈ÷ À¯¿ëÇÕ´Ï´Ù. ¶ÇÇÑ, ¶ó¸¸ ºÐ±¤¹ý, ±ÙÀû¿Ü¼±(NIR) ºÐ±¤¹ý, Áú·®ºÐ¼®¹ý µîÀÇ »õ·Î¿î ±â¼úÀÌ ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ¸ð´ÏÅ͸µ¿¡ Àû¿ëµÇ¾î º¹ÀâÇÑ »ý¹°ÇÐÀû È¥ÇÕ¹°ÀÇ ºñħ½ÀÀû ½Ç½Ã°£ ÃøÁ¤ÀÌ °¡´ÉÇØÁ³½À´Ï´Ù. ÀÌ·¯ÇÑ º¯¼ö¸¦ ½Ç½Ã°£À¸·Î ÃßÀûÇÒ ¼ö ÀÖ´Â ´É·ÂÀº Á¦Ç° ǰÁúÀ» º¸ÀåÇÒ »Ó¸¸ ¾Æ´Ï¶ó ´Ù¿îŸÀÓ°ú ³¶ºñ¸¦ ÁÙ¿© º¸´Ù Áö¼Ó°¡´ÉÇÑ Á¦Á¶ °øÁ¤À» ¸¸µé¾î³À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ºÐ¼®ÀÇ ¼¼ºÐÈ­ ¹× Á¤¹Ðµµ¸¦ Çâ»ó½ÃÄÑ »ý¹°ÇÐÀû Á¦Á¦ Á¦Á¶ÀÇ ÁøÈ­¿¡ ÇʼöÀûÀÎ µµ±¸°¡ µÇ°í ÀÖ½À´Ï´Ù.

Àü ¼¼°èÀûÀ¸·Î ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ºÐ¼®ÀÇ Ã¤ÅÃÀ» °¡¼ÓÈ­Çϰí ÀÖ´Â ½ÃÀå ¹× ±ÔÁ¦ µ¿ÇâÀº ¹«¾ùÀΰ¡?

¼¼°è ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©¿Í ½ÃÀåÀÇ ±â´ë´Â ÷´Ü ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ºÐ¼®ÀÇ Ã¤ÅÃÀ» Á¡Á¡ ´õ ÃËÁøÇϰí ÀÖÀ¸¸ç, ±â¾÷µéÀº ÀÌ·¯ÇÑ ½Ã½ºÅÛÀ» ±âÁ¸ ¹× ½Å±Ô »ý»ê ¶óÀο¡ ÅëÇÕÇϵµ·Ï Àå·ÁÇϰí ÀÖ½À´Ï´Ù. FDA, EMA, PMDA¿Í °°Àº ±ÔÁ¦ ±â°üÀº À§Çè ±â¹Ý Á¢±Ù ¹æ½Ä°ú Áö¼ÓÀûÀÎ ¸ð´ÏÅ͸µ¿¡ ÃÊÁ¡À» ¸ÂÃß°í, Á¦Á¶¾÷ü°¡ °øÁ¤ ºÐ¼® ±â¼ú°ú ¼³°è¿¡ ÀÇÇÑ Ç°Áú ¿øÄ¢À» äÅÃÇϵµ·Ï Àå·ÁÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÇÁ·¹ÀÓ¿öÅ©´Â ÇÁ·Î¼¼½ºÀÇ º¯µ¿¼º°ú Áß¿äÇÑ Ç°Áú ¼Ó¼º¿¡ ´ëÇÑ ±íÀº ÀÌÇØ°¡ ÇÊ¿äÇϸç, ÀÌ´Â °­·ÂÇÑ ºÐ¼® µµ±¸¸¦ ÅëÇØ¼­¸¸ ´Þ¼ºÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ¿¡ µû¶ó, ¹ÙÀÌ¿ÀÁ¦¾à ±â¾÷µéÀº ±ÔÁ¤ Áؼö¸¦ ÀÔÁõÇϰí, Á¦Á¶ ÆÄÀÌÇÁ¶óÀÎÀÇ ¸®½ºÅ©¸¦ ÁÙÀ̸ç, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎÀ» º¸´Ù ½Å¼ÓÇÏ°Ô È®º¸Çϱâ À§ÇØ ºÐ¼® ÀÎÇÁ¶ó¿¡ Àû±ØÀûÀ¸·Î ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. ½ÃÀå Ãø¸é¿¡¼­´Â ÀÌÁ߯¯À̼ºÇ×ü, Ç×ü¾à¹°Á¢ÇÕü, °³º°È­ ¼¼Æ÷ Ä¡·áÁ¦ µî »ý¹°ÇÐÀû Á¦Á¦ÀÇ º¹À⼺ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó º¸´Ù ¼¼¹ÐÇÑ °øÁ¤ Á¦¾î¿Í ½Ç½Ã°£ Çǵå¹é ·çÇÁ°¡ ¿ä±¸µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Ä¡¿­ÇÑ °æÀï°ú Á¦Á¶ ºñ¿ë Àý°¨¿¡ ´ëÇÑ ¾Ð¹ÚÀ¸·Î ÀÎÇØ Á¦Á¶¾÷üµéÀº µ¥ÀÌÅÍ ±â¹Ý ÀλçÀÌÆ®¸¦ ÅëÇØ ºÒ·®·üÀ» ÃÖ¼ÒÈ­ÇÏ°í ¼öÀ² È¿À²À» °³¼±Çϱâ À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù. CMO(À§Å¹»ý»ê±â°ü)¿Í CDMO(À§Å¹°³¹ß»ý»ê±â°ü)ÀÇ ¹ßÀÚÃë°¡ È®´ëµÇ°í ÀÖ´Â °Íµµ °øÁ¤ Ç¥ÁØÈ­¸¦ ÅëÇØ ǰÁú°ú Àϰü¼ºÀ» ÅëÇØ Â÷º°È­¸¦ ²ÒÇÏ´Â ÀÌµé »ç¾÷üÀÇ Ã¤Åÿ¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ½ÅÈï±¹¿¡¼­´Â ¹ÙÀÌ¿ÀÀǾàǰ Á¦Á¶ ¿ª·®À» °­È­Çϱâ À§ÇÑ ±¹°¡Àû ³ë·ÂÀÌ ¹Î°ü ÆÄÆ®³Ê½Ê°ú ±¹Á¦ Çù·ÂÀÇ Áö¿øÀ» ¹Þ¾Æ ÃֽŠºÐ¼® µµ±¸ÀÇ µµÀÔÀ» ÃËÁøÇÏ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. ÀÌ·¯ÇÑ ±ÔÁ¦¿Í ½ÃÀå ÃËÁø¿äÀÎÀÌ °áÇյǾî Áö¿ª°ú ½Ã¼³ À¯Çü¿¡ °ü°è¾øÀÌ ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ºÐ¼®ÀÇ ±¤¹üÀ§ÇÑ ÅëÇÕÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ºÐ¼® ½ÃÀå È®´ëÀÇ ÁÖ¿ä ¼ºÀå ÃËÁø¿äÀÎÀº ¹«¾ùÀΰ¡?

¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ºÐ¼® ½ÃÀåÀÇ ¼ºÀåÀº »ê¾÷ ¹ßÀü, ±â¼ú·Â, ±ÔÁ¦ ¸ð¸àÅÒ, Àü·«Àû Á¦Á¶ º¯È­ÀÇ Á¶ÇÕÀ¸·Î ÀÎÇØ ¹ß»ýÇÕ´Ï´Ù. °¡Àå °­·ÂÇÑ ÃËÁø¿äÀÎ Áß Çϳª´Â Ä¡·á¿ë ´Ü¹éÁú, ´ÜŬ·ÐÇ×ü, ¼¼Æ÷ ¹× À¯ÀüÀÚ Ä¡·áÁ¦ µî ¼¼°è ÀǾàǰ ½ÃÀå¿¡¼­ »ý¹°ÇÐÀû Á¦Á¦ÀÇ ºÎ»óÀÔ´Ï´Ù. ¸ÂÃãÇü ÀǷḦ ÇâÇÑ ¿òÁ÷ÀÓÀº ½Ç½Ã°£ ºÐ¼®ÀÇ Çʿ伺À» ´õ¿í °­È­½Ã۰í ÀÖ½À´Ï´Ù. ¹èÄ¡ »çÀÌÁî°¡ ÀÛ°í, ȯÀÚ ¸ÂÃãÇü Ä¡·á¹ý¿¡¼­´Â ¿À·ù³ª µÇµ¹¸± ¼ö ÀÖ´Â ¿©Áö°¡ °ÅÀÇ ¾ø±â ¶§¹®ÀÔ´Ï´Ù. ¼¾¼­, ¼ÒÇÁÆ®¿þ¾î, µ¥ÀÌÅÍ ºÐ¼®ÀÇ ±â¼ú Çõ½ÅÀº º¹ÀâÇÑ ¹ÙÀÌ¿À °øÁ¤ÀÇ º¸´Ù ¼¼¹ÐÇÑ ÀÚµ¿È­µÈ ¿¹Ãø Á¦¾î¸¦ °¡´ÉÇÏ°Ô ÇÏ¿© È¿À²¼º°ú Á¦Ç° ǰÁúÀ» Å©°Ô Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. µ¿½Ã¿¡ ±ÔÁ¦ ´ç±¹Àº ÅëÇÕ Ç°Áú ½Ã½ºÅÛÀÇ Çʿ伺À» °­È­Çϰí, ±ÔÁ¤ Áؼö ¿ä±¸ »çÇ×À» ÃæÁ·ÇÏ°í ½ÂÀÎ ½Ã°£À» ´ÜÃàÇϱâ À§ÇØ Á¦Á¶¾÷ü°¡ ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ºÐ¼®¿¡ ÅõÀÚÇϵµ·Ï Àå·ÁÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¿¬¼Ó »ý»ê ¹× ÀÏȸ¿ë ¹ÙÀÌ¿À¸®¾×ÅÍÀÇ Ã¤ÅÃÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ±Þº¯ÇÏ´Â »ý»ê ¿ªÇп¡ ´ëÀÀÇÒ ¼ö ÀÖ´Â ÀζóÀÎ ¿Â¶óÀÎ ¸ð´ÏÅ͸µ µµ±¸¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀǾàǰ °³¹ß ¹× »ý»ê¿¡¼­ CMO¿Í CDMOÀÇ ¿ªÇÒÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ºÐ¼® ¹æ¹ýÀÇ Ç¥ÁØÈ­°¡ ÃËÁøµÇ¾î ¼ö¿ä°¡ ´õ¿í Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ºñ¿ë Àý°¨°ú ¼öÀ² ±Ø´ëÈ­¿¡ ´ëÇÑ °æÁ¦Àû ¾Ð¹ÚÀ¸·Î ÀÎÇØ ±â¾÷µéÀº Á¦Á¶ ¿î¿µ Àü¹Ý¿¡ °ÉÃÄ µ¥ÀÌÅÍ ±â¹Ý ÀÇ»ç°áÁ¤À» äÅÃÇϰí ÀÖ½À´Ï´Ù. ¼¼°è º¸°Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áö¼ÓÀûÀ¸·Î Áõ°¡ÇÏ°í »ý¹°ÇÐÀû Á¦Á¦°¡ Çö´ë ÀÇÇÐÀÇ Áß½ÉÀÌ µÊ¿¡ µû¶ó, °­·ÂÇÑ ½Ç½Ã°£ ¿¹Ãø ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ºÐ¼®¿¡ ´ëÇÑ ¼ö¿ä´Â ¼±Áø±¹°ú ½ÅÈï±¹ ½ÃÀå ¸ðµÎ¿¡¼­ Å©°Ô Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ºÎ¹®

Á¦Ç°(ħÅõ¾Ð°è, ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ºÐ¼®°è), ¿ëµµ(ÀÓ»ó ¿ëµµ, »ê¾÷ ¿ëµµ), ÃÖÁ¾»ç¿ëÀÚ(¹ÙÀÌ¿ÀÀǾàǰ ±â¾÷ ÃÖÁ¾»ç¿ëÀÚ, ÀǾàǰ ÀÓ»ó½ÃÇè¼öʱâ°ü ÃÖÁ¾»ç¿ëÀÚ, ÀǾàǰ Á¦Á¶¾÷¹«¼öŹ ±â°ü ÃÖÁ¾»ç¿ëÀÚ, ±âŸ ÃÖÁ¾»ç¿ëÀÚ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

Global Industry Analysts´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM ¹× ¾÷°è °íÀ¯ÀÇ SLMÀ» Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹üÀ» µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡°¡ ¼±º°ÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Bioprocessing Analytics Market to Reach US$650.5 Million by 2030

The global market for Bioprocessing Analytics estimated at US$537.4 Million in the year 2024, is expected to reach US$650.5 Million by 2030, growing at a CAGR of 3.2% over the analysis period 2024-2030. Osmometers, one of the segments analyzed in the report, is expected to record a 2.6% CAGR and reach US$414.5 Million by the end of the analysis period. Growth in the Bioprocess Analyzers segment is estimated at 4.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$146.4 Million While China is Forecast to Grow at 5.9% CAGR

The Bioprocessing Analytics market in the U.S. is estimated at US$146.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$127.6 Million by the year 2030 trailing a CAGR of 5.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.3% and 2.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.8% CAGR.

Global Bioprocessing Analytics Market - Key Trends & Drivers Summarized

Why Is Bioprocessing Analytics Becoming Central to Biopharmaceutical Manufacturing?

The increasing complexity of biologic drugs and the high stakes associated with their production have made bioprocessing analytics a vital component in the biopharmaceutical manufacturing process. As biologics such as monoclonal antibodies, cell therapies, and gene therapies become more prominent, ensuring the consistency, safety, and efficacy of these products throughout the production lifecycle is imperative. Bioprocessing analytics involves real-time and offline monitoring of critical quality attributes and process parameters, allowing manufacturers to detect deviations, optimize yields, and maintain regulatory compliance. Traditional methods of quality testing, which relied heavily on post-production analysis, are giving way to integrated analytical tools that enable continuous monitoring and control throughout upstream and downstream processes. This shift aligns with the industry's move toward Quality by Design (QbD) and Process Analytical Technology (PAT) frameworks advocated by regulatory agencies. Bioprocessing analytics helps reduce batch failures, minimize costs, and accelerate time to market by providing actionable insights at every stage of the production pipeline. The growing use of single-use technologies and continuous manufacturing further amplifies the need for robust analytics that can keep pace with dynamic production environments. As the global demand for biologics grows and therapies become more patient-specific, bioprocessing analytics will continue to serve as a cornerstone for achieving operational excellence and regulatory success in biomanufacturing.

How Are Technological Innovations Redefining the Scope and Accuracy of Bioprocessing Analytics?

Rapid advances in sensor technology, data analytics, machine learning, and automation are redefining how bioprocessing analytics are implemented and utilized in real-time manufacturing environments. Modern bioprocessing systems are now equipped with advanced inline and at-line sensors capable of continuously monitoring parameters such as pH, dissolved oxygen, temperature, turbidity, cell density, and metabolite concentrations with unprecedented precision. These sensors feed data into sophisticated control systems that allow for predictive adjustments, helping maintain optimal conditions and improve overall process stability. At the same time, machine learning algorithms and artificial intelligence are being employed to analyze vast datasets generated during production, enabling the early detection of anomalies and pattern recognition that would be impossible through manual oversight alone. Cloud-based platforms and integrated software suites are facilitating centralized data management, remote access, and cross-site comparisons, which are especially beneficial for multinational companies managing multiple facilities. Additionally, novel techniques such as Raman spectroscopy, near-infrared (NIR) spectroscopy, and mass spectrometry are being adapted for bioprocess monitoring, allowing for non-invasive and real-time measurements of complex biological mixtures. The ability to track these variables in real time not only ensures product quality but also reduces downtime and waste, creating a more sustainable manufacturing process. These technological innovations are enhancing both the granularity and accuracy of bioprocessing analytics, making them indispensable tools in the evolving landscape of biologics production.

What Market and Regulatory Trends Are Accelerating the Adoption of Bioprocessing Analytics Globally?

Global regulatory frameworks and market expectations are increasingly favoring the adoption of advanced bioprocessing analytics, prompting companies to integrate these systems into both existing and new production lines. Regulatory bodies such as the FDA, EMA, and PMDA have shifted their focus toward risk-based approaches and continuous monitoring, encouraging manufacturers to adopt Process Analytical Technology and Quality by Design principles. These frameworks require a deep understanding of process variability and critical quality attributes, which can only be achieved through robust analytical tools. In response, biopharmaceutical companies are proactively investing in analytics infrastructure to demonstrate compliance, de-risk their production pipelines, and secure faster regulatory approvals. On the market side, the growing complexity of biologics, including bispecific antibodies, antibody-drug conjugates, and personalized cell therapies, demands more granular process control and real-time feedback loops. Moreover, increased competition and pressure to reduce manufacturing costs are motivating manufacturers to minimize batch failures and improve yield efficiency through data-driven insights. The expanding footprint of contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs) is also contributing to adoption, as these entities seek to standardize processes and differentiate through quality and consistency. In emerging economies, national initiatives to strengthen biopharmaceutical manufacturing capabilities are encouraging the deployment of modern analytics tools, often with support from public-private partnerships and international collaborations. These regulatory and market drivers are working in tandem to propel the widespread integration of bioprocessing analytics across regions and facility types.

What Are the Primary Growth Drivers Behind the Expansion of the Bioprocessing Analytics Market?

The growth in the bioprocessing analytics market is driven by a combination of industry evolution, technological capabilities, regulatory momentum, and strategic manufacturing shifts. One of the most powerful drivers is the rise of biologics in the global pharmaceutical market, including therapeutic proteins, monoclonal antibodies, and cell and gene therapies, all of which require stringent process control to ensure batch-to-batch consistency. The movement toward personalized medicine is further intensifying the need for real-time analytics, as smaller batch sizes and patient-specific therapies allow little room for error or rework. Technological innovation in sensors, software, and data analytics is enabling more granular, automated, and predictive control over complex bioprocesses, greatly enhancing efficiency and product quality. At the same time, regulatory agencies are reinforcing the need for integrated quality systems, encouraging manufacturers to invest in bioprocessing analytics to satisfy compliance requirements and reduce time to approval. The increasing adoption of continuous manufacturing and single-use bioreactors is also driving demand for in-line and on-line monitoring tools that can keep pace with fast-changing production dynamics. Additionally, the growing role of CMOs and CDMOs in drug development and production is fostering widespread standardization of analytical practices, further boosting demand. Economic pressures to reduce costs and maximize yields are prompting companies to adopt data-driven decision-making throughout their manufacturing operations. As global health demands continue to rise and biologic therapies become more central to modern medicine, the need for robust, real-time, and predictive bioprocessing analytics is expected to grow exponentially, driving expansion across both developed and emerging markets.

SCOPE OF STUDY:

The report analyzes the Bioprocessing Analytics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Osmometers, Bioprocess Analyzers); Application (Clinical Application, Industrial Application); End-User (Biopharmaceutical Companies End-User, Contract Research Organizations End-User, Contract Manufacturing Organizations End-User, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â